GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
May 29, 2018 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
May 10, 2018 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
May 08, 2018 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session
March 14, 2018 08:00 ET
|
Daxor Corporation
(NYSE MKT LLC: DXR) New York, NY, March 14, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations,...
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
February 14, 2018 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
CHF Solutions, Inc. to Present at the LD Micro 10th Annual Main Event on December 5, 2017
November 30, 2017 07:15 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Nov. 30, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that Claudia Drayton, Chief Financial Officer will be a featured presenter at the LD Micro...
CHF Solutions, Inc. Announces Pricing of $18.0 Million Underwritten Public Offering
November 22, 2017 08:30 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock,...
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
November 16, 2017 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
CHF Solutions’ Aquadex FlexFlow® Aquapheresis System Receives FDA IDE Approval for Clinical Study for Pediatric Use
June 29, 2017 07:00 ET
|
CHF Solutions
EDEN PRAIRIE, Minn., June 29, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc., (fka Sunshine Heart, Inc.) (NASDAQ:CHFS) announced today that researchers in the Stanford University School of Medicine’s...
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017
June 20, 2017 08:30 ET
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation Gencaro Development Program Previously Granted Fast Track Designation by U.S. FDA ...